The study had a double-blind , randomized , ascending single-dose design with an oral formulation F@ ( i.e. , ACT-@ or placebo ) ( Part I ) and an open-label , randomized , @-period , crossover design comparing exploratory formulations of ACT-@ ( F@ ) @mg and ACT-@ ( dF ) @mg to F@ @mg ( Part II ) .